Patent ID: 11891618
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Biotechnology (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 26:
27. A method of optimizing the activity of a human-TTR-targeting reagent in vivo, comprising:
(I) performing the method of claim 26 a first time in a first mouse comprising in its genome the genetically modified endogenous Ttr locus;
(II) changing a variable and performing the method of step (I) a second time with the changed variable in a second mouse comprising in its genome the genetically modified endogenous Ttr locus; and
(III) comparing the activity of the human-TTR-targeting reagent in step (I) with the activity of the human-TTR-targeting reagent in step (II), and selecting the method resulting in the higher efficacy, higher precision, higher consistency, or higher specificity.